Cure8

Why This Matters

Patients with multiple biologic failures appear more likely to have inflammatory comorbidities (including IBD) and to experience worse dermatology-related quality of life despite similar early skin improvement. That could affect monitoring and care planning.

Who Should Pay Attention

Clinicians managing psoriasis, researchers studying biologic treatment resistance, and adult patients with psoriasis—especially those with multiple prior biologic therapies or known inflammatory comorbidities.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The study used a single-centre retrospective design and identified 50 of 545 patients as having multiple biologic failure. Associations were observed between MBF and inflammatory comorbidity, multimorbidity, and lower rates of optimal dermatology quality-of-life (DLQI 0/1) at weeks 12–16, while PASI90 skin responses were similar.

The IBD association was based on a small number of patients (n=12) and the authors describe it as hypothesis-generating. The findings may reflect biological refractoriness, treatment-pathway complexity (treatment sequencing, interruptions, or access issues), or both; the study design cannot fully separate these possibilities.

If you live with psoriasis and have multiple treatment failures, these results highlight the importance of evaluating comorbid inflammatory conditions and discussing quality-of-life concerns with your care team.

Keep In Mind

This is a single-centre, retrospective cohort reported as an abstract-level/full-text preprint on Research Square; the IBD association was based on only 12 patients and is hypothesis-generating. The study cannot prove causation or fully separate biological resistance from treatment-pathway factors.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationSpringer Science and Business Media LLC
AuthorsJosé Molina-Espinosa, Pedro José Ezomo-Gervilla, Diego Gallego-García +3 more
Study typePosted Content
Indexed viaCrossref
Source typeResearch paper
PublishedOct 4, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →